Łukasz Skalniak (Lukasz Skalniak)

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 26

Top Topics

Molecular Dynamics Simulations

Benign Prostatic Hyperplasia

Human Serum Albumin

Top Venues

Molecules (Basel, Switzerland)

Journal of medicinal chemistry

Expert opinion on therapeutic patents

Archiv der Pharmazie

This page only lists publications with an associated author ORCID identifier.

Publications

Joanna Klimek, Oskar Kruc, Joanna Ceklarz, Beata Kaminska, Bogdan M Musielak, Robin van der Straat, Alexander S S Dömling, Tad A Holak, Damian Muszak, Justyna Kalinowska-Tluscik, Łukasz Skalniak, Ewa Surmiak
C2-Symmetrical Terphenyl Derivatives as Small Molecule Inhibitors of Programmed Cell Death 1/Programmed Death Ligand 1 Protein-Protein Interaction. Molecules (Basel, Switzerland) 29 (11) (2024)
Joanna Klimek, Oskar Kruc, Joanna Ceklarz, Beata Kaminska, Bogdan M Musielak, Robin van der Straat, Alexander S S Dömling, Tad A Holak, Damian Muszak, Justyna Kalinowska-Tluscik, Łukasz Skalniak, Ewa Surmiak
C2-Symmetrical Terphenyl Derivatives as Small Molecule Inhibitors of Programmed Cell Death 1/Programmed Death Ligand 1 Protein-Protein Interaction. Molecules (Basel, Switzerland) 29 (11) (2024)
Joanna Klimek, Oskar Kruc, Joanna Ceklarz, Beata Kaminska, Bogdan M Musielak, Robin van der Straat, Alexander S S Dömling, Tad A Holak, Damian Muszak, Justyna Kalinowska-Tluscik, Łukasz Skalniak, Ewa Surmiak
C2-Symmetrical Terphenyl Derivatives as Small Molecule Inhibitors of Programmed Cell Death 1/Programmed Death Ligand 1 Protein-Protein Interaction. Molecules (Basel, Switzerland) 29 (11) (2024)
Wiktor Uzar, Beata Kaminska, Hubert Rybka, Łukasz Skalniak, Katarzyna Magiera-Mularz, Radoslaw Kitel
An updated patent review on PD-1/PD-L1 antagonists (2022-present). Expert opinion on therapeutic patents 34 (8) (2024)
Wiktor Uzar, Beata Kaminska, Hubert Rybka, Łukasz Skalniak, Katarzyna Magiera-Mularz, Radoslaw Kitel
An updated patent review on PD-1/PD-L1 antagonists (2022-present). Expert opinion on therapeutic patents 34 (8) (2024)
Wiktor Uzar, Beata Kaminska, Hubert Rybka, Łukasz Skalniak, Katarzyna Magiera-Mularz, Radoslaw Kitel
An updated patent review on PD-1/PD-L1 antagonists (2022-present). Expert opinion on therapeutic patents (2024)
Ewa Surmiak, Julia Ząber, Jacek Plewka, Grzegorz Wojtanowicz, Justyna Kocik-Krol, Oskar Kruc, Damian Muszak, Ismael Rodriguez, Bogdan M Musielak, Monica Viviano, Sabrina Castellano, Łukasz Skalniak, Katarzyna Magiera-Mularz, Tad A Holak, Justyna Kalinowska-Tłuścik
Solubilizer Tag Effect on PD-L1/Inhibitor Binding Properties for m -Terphenyl Derivatives. ACS medicinal chemistry letters 15 (1) (2023)
Greta Donati, Monica Viviano, Vincenzo Maria D'Amore, Alessandra Cipriano, Isidora Diakogiannaki, Jussara Amato, Stefano Tomassi, Diego Brancaccio, Pasquale Russomanno, Francesco Saverio Di Leva, Daniela Arosio, Pierfausto Seneci, Sabrina Taliani, Katarzyna Magiera-Mularz, Bogdan Musielak, Łukasz Skalniak, Tad A Holak, Sabrina Castellano, Valeria La Pietra, Luciana Marinelli
A combined approach of structure-based virtual screening and NMR to interrupt the PD-1/PD-L1 axis: Biphenyl-benzimidazole containing compounds as novel PD-L1 inhibitors. Archiv der Pharmazie 357 (3) (2023)
Ewa Surmiak, Julia Ząber, Jacek Plewka, Grzegorz Wojtanowicz, Justyna Kocik-Krol, Oskar Kruc, Damian Muszak, Ismael Rodriguez, Bogdan M Musielak, Monica Viviano, Sabrina Castellano, Łukasz Skalniak, Katarzyna Magiera-Mularz, Tad A Holak, Justyna Kalinowska-Tłuścik
Solubilizer Tag Effect on PD-L1/Inhibitor Binding Properties for m -Terphenyl Derivatives. ACS medicinal chemistry letters 15 (1) (2023)
Greta Donati, Monica Viviano, Vincenzo Maria D'Amore, Alessandra Cipriano, Isidora Diakogiannaki, Jussara Amato, Stefano Tomassi, Diego Brancaccio, Pasquale Russomanno, Francesco Saverio Di Leva, Daniela Arosio, Pierfausto Seneci, Sabrina Taliani, Katarzyna Magiera-Mularz, Bogdan Musielak, Łukasz Skalniak, Tad A Holak, Sabrina Castellano, Valeria La Pietra, Luciana Marinelli
A combined approach of structure-based virtual screening and NMR to interrupt the PD-1/PD-L1 axis: Biphenyl-benzimidazole containing compounds as novel PD-L1 inhibitors. Archiv der Pharmazie 357 (3) (2023)
Greta Donati, Monica Viviano, Vincenzo Maria D'Amore, Alessandra Cipriano, Isidora Diakogiannaki, Jussara Amato, Stefano Tomassi, Diego Brancaccio, Pasquale Russomanno, Francesco Saverio Di Leva, Daniela Arosio, Pierfausto Seneci, Sabrina Taliani, Katarzyna Magiera-Mularz, Bogdan Musielak, Łukasz Skalniak, Tad A Holak, Sabrina Castellano, Valeria La Pietra, Luciana Marinelli
A combined approach of structure-based virtual screening and NMR to interrupt the PD-1/PD-L1 axis: Biphenyl-benzimidazole containing compounds as novel PD-L1 inhibitors. Archiv der Pharmazie (2023)
Shabnam Shaabani, Louis Gadina, Ewa Surmiak, Zefeng Wang, Bidong Zhang, Roberto Butera, Tryfon Zarganes-Tzitzikas, Ismael Rodriguez, Justyna Kocik-Krol, Katarzyna Magiera-Mularz, Łukasz Skalniak, Alexander S S Dömling, Tad A Holak
Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. Molecules (Basel, Switzerland) 27 (11) (2022)
Bartłomiej Bazan, Aleksandra Pałasz, Łukasz Skalniak, Dariusz Cież, Szymon Buda, Katarzyna Jędrzejowska, Sonia Głomb, Daniel Kamzol, Kinga Czarnota, Krystian Latos, Krzysztof Kozieł, Bogdan M Musielak
Application of bioorthogonal hetero-Diels-Alder cycloaddition of 5-arylidene derivatives of 1,3-dimethylbarbituric acid and vinyl thioether for imaging inside living cells. Organic & biomolecular chemistry 19 (27) (2021)
Aleksandra Wesełucha-Birczyńska, Anna Kołodziej, Małgorzata Świętek, Łukasz Skalniak, Elżbieta Długoń, Maria Pajda, Marta Błażewicz
Early Recognition of the PCL/Fibrous Carbon Nanocomposites Interaction with Osteoblast-like Cells by Raman Spectroscopy. Nanomaterials (Basel, Switzerland) 11 (11) (2021)
Damian Muszak, Ewa Surmiak, Jacek Plewka, Katarzyna Magiera-Mularz, Justyna Kocik-Krol, Bogdan M Musielak, Dominik Sala, Radoslaw Kitel, Malgorzata Stec, Kazimierz Weglarczyk, Maciej Siedlar, Alexander S S Dömling, Łukasz Skalniak, Tad A Holak
Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction. Journal of medicinal chemistry 64 (15) (2021)
Natalia Kłeczek, Janusz Malarz, Barbara Gierlikowska, Łukasz Skalniak, Agnieszka Galanty, Anna Karolina Kiss, Anna Stojakowska
Germacranolides from Carpesium divaricatum: Some New Data on Cytotoxic and Anti-Inflammatory Activity. Molecules (Basel, Switzerland) 26 (15) (2021)
Ewa Surmiak, Katarzyna Magiera-Mularz, Bogdan M Musielak, Damian Muszak, Justyna Kocik-Krol, Radoslaw Kitel, Jacek Plewka, Tad A Holak, Łukasz Skalniak
PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action. International journal of molecular sciences 22 (21) (2021)
Magdalena Konieczny, Bogdan M Musielak, Justyna Kocik-Krol, Łukasz Skalniak, Dominik Sala, Miroslawa Czub, Katarzyna Magiera-Mularz, Ismael Rodriguez, Maja Myrcha, Malgorzata Stec, Maciej Siedlar, Tad A Holak, Jacek Plewka
Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint. Journal of medicinal chemistry 63 (19) (2020)
Justyna Kocik-Krol, Monika Machula, Aneta Wisniewska, Ewa Surmiak, Tad A Holak, Łukasz Skalniak
Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists. Cancers 11 (7) (2019)
Subhadwip Basu, Jeffrey Yang, Bin Xu, Katarzyna Magiera-Mularz, Łukasz Skalniak, Bogdan Musielak, Vladyslav Kholodovych, Tad A Holak, Longqin Hu
Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction. Journal of medicinal chemistry 62 (15) (2019)
Łukasz Skalniak, Aleksandra Twarda-Clapa, Constantinos G Neochoritis, Ewa Surmiak, Monika Machula, Aneta Wisniewska, Beata Labuzek, Ameena M Ali, Sylwia Krzanik, Grzegorz Dubin, Matthew Groves, Alexander Dömling, Tad A Holak
A fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53wt osteosarcoma cells. The FEBS journal 286 (7) (2019)
Bogdan M Musielak, Justyna Kocik-Krol, Łukasz Skalniak, Katarzyna Magiera-Mularz, Dominik Sala, Miroslawa Czub, Malgorzata Stec, Maciej Siedlar, Tad A Holak, Jacek Plewka
CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not? Molecules (Basel, Switzerland) 24 (15) (2019)
Łukasz Skalniak, Ewa Surmiak, Tad A Holak
A therapeutic patent overview of MDM2/X-targeted therapies (2014-2018). Expert opinion on therapeutic patents 29 (3) (2019)
Łukasz Skalniak, Justyna Kocik-Krol, Justyna Polak, Anna Skalniak, Monika Rak, Agnieszka Wolnicka-Glubisz, Tad A Holak
Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells. Cancers 10 (11) (2018)
Aleksandra Twarda-Clapa, Sylwia Krzanik, Katarzyna Kubica, Katarzyna Guzik, Beata Labuzek, Constantinos G Neochoritis, Kareem Khoury, Kaja Kowalska, Miroslawa Czub, Grzegorz Dubin, Alexander S S Dömling, Łukasz Skalniak, Tad A Holak
1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers. Journal of medicinal chemistry 60 (10) (2017)
Katarzyna Guzik, Krzysztof M Zak, Przemyslaw Grudnik, Katarzyna Magiera, Bogdan Musielak, Ricarda Törner, Łukasz Skalniak, Alexander S S Dömling, Grzegorz Dubin, Tad A Holak
Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. Journal of medicinal chemistry 60 (13) (2017)